CEBPZ and acute myeloid leukemia: In conclusion, our study suggests that azacitidine maintenance therapy may confer a benefit in sustaining molecular remission for specific subgroups of pediatric AML, particularly patients with CBF-AML and persistent MRD after induction who are ineligible for HSCT.